Brucellosis Epidemiology

Key Highlights

• Brucellosis is a serious infectious disease that can affect people of all ages, including children. It occurs when brucella bacteria enter the body through contact with infected animals or consumption of contaminated animal products, leading to systemic infection.
• Our secondary analysis indicates that approximately 200 cases of brucellosis occur annually in the US. 
• In France, secondary research indicates that brucellosis has an incidence of 0.051 per 100,000, underscoring the rarity of the disease but also the importance of maintaining vigilance for timely diagnosis.
• Secondary research shows that in Germany, males bear a slightly greater burden of brucellosis compared to females, accounting for 54% of reported cases versus 46% in females, indicating a modest male predominance.
• Despite existing surveillance efforts, there is a significant unmet need for comprehensive and timely epidemiological data on brucellosis. Limited reporting accuracy and underdiagnoses, especially in non-endemic regions, hinder effective tracking of disease burden, delay public health responses.
• Brucellosis diagnosis remains challenging due to the absence of rapid, infection-specific testing methods. The limited availability of advanced diagnostic tools hampers timely detection, contributing to underreporting and an incomplete understanding of its true epidemiological burden.

DelveInsight’s “Brucellosis – Epidemiology Forecast – 2034” report delivers an in-depth understanding of brucellosis, historical and forecasted epidemiology trends in the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan. 

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2020–2034

Disease Understanding

Brucellosis Overview

Brucellosis is a systemic bacterial infection primarily transmitted from animals to humans, causing a wide range of acute and chronic symptoms. It results from infection with brucella species, which invade and survive within immune cells, leading to prolonged inflammation and tissue damage. The disease can develop gradually or suddenly and is often triggered by exposure to infected animals, consumption of unpasteurized dairy products, or occupational contact.

Brucellosis commonly manifests with fever, night sweats, malaise, joint and muscle pain, and fatigue. In more severe or prolonged cases, it may progress to complications such as arthritis, spondylitis, endocarditis, or neurological involvement.

Brucellosis Diagnosis

The diagnosis of brucellosis is primarily based on laboratory testing rather than imaging, with key markers including positive blood cultures for brucella species, elevated antibody titers, and molecular detection by Polymerase Chain Reaction (PCR). Symptoms often develop gradually, with early signs such as intermittent fever, night sweats, fatigue, and joint pain commonly reported. In more severe or chronic cases, patients may present with organ-specific complications like arthritis, endocarditis, or neurological symptoms.

Severity is assessed through clinical evaluation and laboratory findings, including inflammatory markers and evidence of organ involvement. If not diagnosed and treated promptly, brucellosis can lead to serious complications such as osteoarticular damage, endocarditis, neurobrucellosis, and rarely death.

For More Insights into the Report @ Brucellosis Treatment Market

Brucellosis Epidemiology

The brucellosis epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total incident cases of brucellosis, gender–specific incident cases of brucellosis, and treated cases of brucellosis in the 7MM covering, the United States, EU4 countries (Germany, France, Italy, and Spain), United Kingdom, and Japan from 2020 to 2034. 

• In Spain, the incidence of brucellosis is 0.043 per 100,000 with cases occurring across all age groups but showing notable variation by age, underscoring the need for targeted surveillance in higher-risk populations.
• In Italy, the incidence of brucellosis is 0.082 per 100,000 with cases reported across all age groups, emphasizing the importance of continuous monitoring to detect and control potential outbreaks.
• Secondary sources reveal that in 2024, more than 30 cases of brucellosis were reported in the United Kingdom, indicating the infection’s continued occurrence within the country during that year.
• Unmet needs include the lack of robust epidemiological data in regions with low brucellosis incidence, which hampers accurate assessment of transmission patterns and risk profiles. This data gap restricts early detection of emerging clusters and limits the development of proactive, evidence-based control strategies.

KOL Views

DelveInsight’s analysts collaborated with over 50 key opinion leaders (KOLs), conducting in-depth interviews with more than 15 experts across the 7MM. To keep pace with dynamic epidemiology trends, the team gathered first-hand insights from KOLs and subject matter experts (SMEs) through primary research, addressing data limitations and reinforcing findings from secondary research. These professionals offered valuable input on the brucellosis landscape and highlighting patient behavior trends. Contributors included experts from renowned institutions such as the Campbell University School of Osteopathic Medicine, US; Friedrich Loeffler Institute, Germany; University Hospital Caremeau, France; Chair Metabolic University of Messina, Italy; University of Málaga, Spain; University of Southampton, the UK; Sapporo Medical University, Japan and Rakuno Gakuen University, Japan, among others.

As per KOLs from the US, “A substantial proportion of brucellosis cases go undiagnosed, particularly in non-endemic areas where clinical suspicion is low. Experts emphasize that its non-specific, flu-like symptoms often lead to misdiagnosis or delayed recognition, allowing the infection to progress and increasing the risk of severe complications. This diagnostic gap highlights the critical need for improved awareness, accessible confirmatory testing, and targeted screening in at-risk populations to reduce missed cases and improve patient outcomes”.

KOLs from Germany, “Highlight that delayed or missed diagnosis of brucellosis remains a significant challenge, particularly in regions with low disease incidence. Many cases are identified only after advanced symptoms appear or during hospital admissions, emphasizing the need for greater clinical awareness, consistent diagnostic practices, and earlier detection to reduce the risk of severe outcomes”. 

KOLs from Japan, “Highlight that the absence of robust, nationally coordinated surveillance systems for brucellosis, even in non-endemic settings, poses a significant challenge. Many cases, particularly imported or chronic infections, go unrecognized in routine practice, resulting in delayed diagnosis and exposure risks, including for laboratory personnel. Experts call for more systematic surveillance measures, enhanced clinical-laboratory communication, and improved awareness to ensure early detection and effective response”.

Scope of the Report

• The report covers a segment of executive summary, descriptive overview of brucellosis, explaining its causes, signs and symptoms, and currently available diagnostic algorithms and guidelines.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and diagnosis guidelines.
• The report provides an edge for understanding trends, expert insights/KOL views, and patient journeys in the 7MM.
• A detailed review of current challenges in establishing the diagnosis.

Brucellosis Report Insights

• Patient Population
• Country-wise Epidemiology Distribution
• Total Incident Cases of Brucellosis 
• Gender–specific Incident Cases of Brucellosis 
• Treated Cases of Brucellosis

Brucellosis Report Key Strengths

• 10 years Forecast
• The 7MM Coverage 

Key Questions

Epidemiology Insights

• What are the disease risk, burden, and unmet needs of brucellosis?
• What is the historical brucellosis patient population in the United States, EU4 (Germany, France, Italy, Spain) and the UK, and Japan?
• What would be the forecasted patient population of brucellosis at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to brucellosis?
• Out of the above-mentioned countries, which country would have the highest incident population of brucellosis during the forecast period (2025–2034)?
• At what Compound annual growth rate (CAGR) the population is expected to grow across the 7MM during the forecast period (2025–2034)?

Reasons to Buy

• Insights on patient burden/disease Incident, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To analyze epidemiological trends of brucellosis across different regions and assess how these patterns may evolve in the coming years.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
• To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis options.

Stay updated with us for Recent Articles @ New DelveInsight Blogs